Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
ACS Appl Mater Interfaces ; 16(22): 28209-28221, 2024 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-38778020

RESUMO

Diabetic chronic wounds are notoriously difficult to heal as a result of their susceptibility to infection. To address this issue, we constructed an innovated and adaptable solution in the form of injectable chitosan (CS) hydrogel, denoted as CCOD, with enhanced antibacterial and anti-inflammatory properties. This hydrogel is created through a Schiff base reaction that combines chitosan-grafted chlorogenic acid (CS-CGA) and oxidized hyaluronic acid (OHA) with deferoxamine (DFO) as a model drug. The combination of CS and CGA has demonstrated excellent antibacterial and anti-inflammatory properties, while grafting played a pivotal role in making these positive effects stable. These unique features make it possible to customize injectable hydrogel and fit any wound shape, allowing for more effective and personalized treatment of complex bacterial infections. Furthermore, the hydrogel system is not only effective against inflammation and bacterial infections but also possesses antioxidant and angiogenic abilities, making it an ideal solution for the repair of chronic wounds that have been previously thought of as unmanageable.


Assuntos
Antibacterianos , Anti-Inflamatórios , Quitosana , Ácido Clorogênico , Desferroxamina , Ácido Hialurônico , Hidrogéis , Cicatrização , Animais , Humanos , Camundongos , Angiogênese , Indutores da Angiogênese/química , Indutores da Angiogênese/farmacologia , Antibacterianos/química , Antibacterianos/farmacologia , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacologia , Quitosana/química , Quitosana/farmacologia , Ácido Clorogênico/química , Ácido Clorogênico/farmacologia , Desferroxamina/química , Desferroxamina/farmacologia , Ácido Hialurônico/química , Ácido Hialurônico/farmacologia , Hidrogéis/química , Hidrogéis/farmacologia , Neovascularização Fisiológica/efeitos dos fármacos , Oxirredução , Staphylococcus aureus/efeitos dos fármacos , Cicatrização/efeitos dos fármacos
2.
Carbohydr Polym ; 292: 119695, 2022 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-35725183

RESUMO

The use of cisplatin is restricted by systemic toxicity and drug resistance. Supramolecular nano-drug delivery systems involving drugs as building blocks circumvent these limitations promisingly. Herein, we describe a novel supramolecular system [Pt(IV)-SSNPs] based on poly(ß-cyclodextrin), which was synthesized for efficient loading of adamantly-functionalized platinum(IV) prodrug [Pt(IV)-ADA2] via the host-guest interaction between ß-cyclodextrin and adamantyl. Pt(IV)-ADA2 can be converted to active cisplatin in reducing environment in cancer cells, which further reduces systemic toxicity. The introduction of the adamantane group-tethered mPEG2k endowed the Pt(IV)-SSNPs with a longer blood circulation time. In vitro assays exhibited that the Pt(IV)-SSNPs could be uptaken by CT26 cells, resulting in cell cycle arrest in the G2/M and S phases, together with apoptosis. Furthermore, the Pt(IV)-SSNPs showed effective tumor accumulation, better antitumor effect, and negligible cytotoxicity to major organs. These results indicate that supramolecular nanoparticles are a promising platform for efficient cisplatin delivery and cancer treatment.


Assuntos
Antineoplásicos , Cisplatino , Neoplasias , Pró-Fármacos , beta-Ciclodextrinas , Animais , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Cisplatino/farmacologia , Camundongos , Neoplasias/tratamento farmacológico , Platina , Pró-Fármacos/farmacologia , Propilenoglicóis
3.
Acta Biomater ; 144: 67-80, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-35331940

RESUMO

Gemcitabine, as a standard and classic strategy for B-cell lymphoma in the clinic, is limited by its poor pharmacodynamics. Although stimuli-responsive polymeric nanodelivery systems have been widely investigated in the past decade, issues such as complicated procedures, low loading capacity, and uncontrollable release kinetics still hinder their clinical translation. In view of the above considerations, we attempt to construct hyperbranched polyprodrug micelles with considerable drug loading via simple procedures and make use of the particularity of the tumor microenvironment to ensure that the micelles are "inactivated" in normal tissues and "activated" in the tumor microenvironment. Hence, in this work, a redox-responsive polymeric gemcitabine-prodrug (GEM-S-S-PEG) was one-pot synthesized via facile esterification and acylation. The self-assembled subsize (< 100 nm) GEM-S-S-PEG (GSP NPs) with considerable loading capacity (≈ 24.6%) exhibited on-demand and accurate control of gemcitabine release under a simulated tumor microenvironment and thus significantly induced the apoptosis of B-cell lymphoma in vitro. Moreover, in the A20 tumor xenograft murine model, GSP NPs efficiently decreased the expansion of tumor tissues with minimal systemic toxicity. In summary, these redox-responsive and self-assembling GSP NPs with a facile one-pot synthesis procedure may hold great potency in clinical translation for enhanced chemotherapy of B-cell lymphoma. STATEMENT OF SIGNIFICANCE: A redox-responsive polymeric gemcitabine-prodrug (GEM-S-S-PEG) was one-pot synthesized via facile esterification and acylation. The self-assembled subsize (< 100 nm) GEM-S-S-PEG (GSP NPs) exhibited significant tumor therapeutic effects in vitro and in vivo. The polyprodrug GEM-S-S-PEG prepared in this study shows the great potential of redox-responsive nanodrugs for antitumor activity, which provides a reference value for the optimization of the design of functional polyprodrugs.


Assuntos
Linfoma de Células B , Linfoma , Nanopartículas , Neoplasias , Pró-Fármacos , Animais , Linhagem Celular Tumoral , Desoxicitidina/análogos & derivados , Sistemas de Liberação de Medicamentos , Humanos , Linfoma/tratamento farmacológico , Linfoma de Células B/tratamento farmacológico , Camundongos , Micelas , Neoplasias/tratamento farmacológico , Oxirredução , Polímeros/uso terapêutico , Pró-Fármacos/farmacologia , Microambiente Tumoral , Gencitabina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA